TBB
CAS No. 17374-26-4
TBB( NSC 231634 | Tetrabromobenzotriazole )
Catalog No. M12636 CAS No. 17374-26-4
TBB(NSC 231634) is a highly selective, ATP/GTP-competitive inhibitor of casein kinase-2 (CK2)with IC50s of 0.9 and 1.6 μM for rat liver and human recombinant CK2 respectively).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 28 | In Stock |
|
| 5MG | 36 | In Stock |
|
| 10MG | 51 | In Stock |
|
| 25MG | 65 | In Stock |
|
| 50MG | 75 | In Stock |
|
| 100MG | 114 | In Stock |
|
| 200MG | 166 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTBB
-
NoteResearch use only, not for human use.
-
Brief DescriptionTBB(NSC 231634) is a highly selective, ATP/GTP-competitive inhibitor of casein kinase-2 (CK2)with IC50s of 0.9 and 1.6 μM for rat liver and human recombinant CK2 respectively).
-
DescriptionTBB(NSC 231634) is a highly selective, ATP/GTP-competitive inhibitor of casein kinase-2 (CK2)with IC50s of 0.9 and 1.6 μM for rat liver and human recombinant CK2 respectively).
-
In VitroInvestigation of the inhibitory power of TBB with a panel of 33 protein kinases shows highest potency for CK2 (casein kinase 2) (human CK2: IC50=1.6 μM at 100 μM ATP). TBB also inhibits three other kinases with less potency: CDK2 (IC50=15.6 μM), phosphorylase kinase (IC50=8.7 μM) and glycogen synthase kinase 3β (GSK3β) (IC50=11.2 μM). All other kinases tested have IC50 values 50-fold greater than that for CK2. The viability of the androgen insensitive PC-3 cells may be diminished by TBB (60 μM TBB) acting either alone or combined with anticancer agents CPT or TRAIL when a proper time schedule of the administration is applied. The time schedule-dependent activity of TBB does not come from its effect on apoptosis in PC-3 cells. TBB is an ATP/GTP competitive inhibitor of protein kinase casein kinase-2 (CK2), has been examined against a panel of 33 protein kinases, either Ser/Thr- or Tyr-specific. In the presence of 10 μM TBB (and 100 μM ATP) only CK2 is drastically inhibited (>85%) whereas three kinases (phosphorylase kinase, glycogen synthase kinase 3L and cyclin-dependent kinase 2/cyclin A) underwent moderate inhibition, with IC50 values one-two orders of magnitude higher than CK2 (IC50=0.9 μM). TBB also inhibits endogenous CK2 in cultured Jurkat cells.
-
In VivoThe extent of retinal neovascularization in a mouse OIR model is reduced by approximately 60% after treatment with TBB (6 days at 60 mg/kg per day).
-
SynonymsNSC 231634 | Tetrabromobenzotriazole
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorCK2| CDK2| GSK-3β
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number17374-26-4
-
Formula Weight434.71
-
Molecular FormulaC6HBr4N3
-
Purity>98% (HPLC)
-
SolubilityDMSO, Ethanol: 100 mM
-
SMILESBrC1=C(NN=N2)C2=C(Br)C(Br)=C1Br
-
Chemical Name4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Orzechowska E, et al. Oncol Rep. 2012 Jan;27(1):281-5.
molnova catalog
related products
-
CDK7 and 9 inhibitor...
A potent, selective transcriptional CDK inhibitor with Ki of 2.3 and 0.38 nM for CDK7 and CDK9, respectively; displays >30-fold selectivity over CDK1/2/4, inhibits VEGFR2 with IC50 of 180 nM in a panel of non-CDK kinases.
-
KB-0742 dihydrochlor...
KB-0742 dihydrochloride is a potent, selective and orally inhibitor of ?CDK9.
-
BAY-958
BAY-958 (BAY958, LDC526)?is a potent, selective PTEFb/CDK9 inhibitor with IC50 of 5 nM against CDK9/CyclinT1.
Cart
sales@molnova.com